StockData
Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc. (ARWR) bonds

ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$42.99−1.22 (-2.76%)

Close on Nov 17, 2026Market cap $6.07BP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Arrowhead Pharmaceuticals reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Notes and loans outstanding

As tagged in Arrowhead Pharmaceuticals's 10-Q for the period ended Jun 30, 2026

IssueCouponAmount issuedCarrying value
Convertible Notes
Convertible at $87 a share
0.00%$700.00M$700.00M
Financing Agreement15.00%––

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySizeAvailableDrawn
Financing Agreement$500.00M$100.00M$400.00M
Financing Agreement, Initial Term Loan––$400.00M
Financing Agreement, Initial Term Loan Interest––$66.94M
Revolving Credit FacilityCN¥72.90M––
Secured Debt––$345.63M

See a number that looks wrong?